Catalyst Calendar

Mon, Jul 13, 2026

1 updates

4:00 AM

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over

Presentation / Abstract • Phase 1/2ISTH oral presentation Mon, Jul 13, 2026, EDTincyte.com

Wed, Jul 8, 2026

1 updates

INCY

8:00 AM

Incyte to Report Second Quarter Financial Results

WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 8, 2026-- Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2

incyte.com

Mon, Jul 6, 2026

1 updates

INCY

8:39 AM

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 6, 2026-- Incyte (Nasdaq:INCY) announced today it has completed its

incyte.com

Fri, Jun 26, 2026

1 updates

INCY

7:30 AM

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

If approved, Opzelura ® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failed AD, the most common type of eczema which affects 230 million people

incyte.com

Fri, Jun 19, 2026

1 updates

INCY

2:00 AM

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 19, 2026-- Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi ® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large

incyte.com

Sun, Jun 14, 2026

1 updates

INCY

4:35 PM

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib

Trial Results • Phase 2ENDO 2026 presentation Sun, Jun 14, 2026, 4:35 PM EDTincyte.com

Sat, Jun 13, 2026

2 updates

INCY

11:15 AM

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinib In essential thrombocythemia (ET), 87% of patients achieved a

Presentation / Abstract • Phase 1EHA 2026 oral presentation Sat, Jun 13, 2026, 11:15 AM EDTincyte.com

INCY

6:00 AM

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

- frontMIND study evaluating tafasitamab (Monjuvi ® /Minjuvi ®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and

Presentation / Abstract • Phase 3Plenary Abstract Session Sat, Jun 13, 2026, 6:00 AM ETincyte.com

Mon, Jun 8, 2026

1 updates

INCY

7:00 AM

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD) - Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones

incyte.com

Thu, Jun 4, 2026

1 updates

INCY

8:05 AM

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) FOSTER CITY, Calif. & WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 4, 2026-- Mirum Pharmaceuticals, Inc.

Presentation / Abstract • Phase 2Late-breaking rapid-fire presentation Sun, Jun 14, 2026, 3:30 PM CTincyte.com

Sat, May 30, 2026

1 updates

INCY

8:00 AM

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi ® /Minjuvi ®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)

Trial Results • Phase 3ASCO oral presentation Sat, May 30, 2026, 4:00 PM ETincyte.com

Tue, May 26, 2026

1 updates

INCY

8:00 AM

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

WILMINGTON, Del. --(BUSINESS WIRE)--May 26, 2026-- Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The presentation will be webcast live and can be accessed at Investor.Incyte.com and

incyte.com

Wed, May 20, 2026

1 updates

INCY

8:00 AM

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data Incyte data will be securely used to train Genesis’ next-generation GEMS AI platform as part of Incyte’s efforts to speed up drug

incyte.com

Tue, May 19, 2026

1 updates

INCY

8:00 AM

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

WILMINGTON, Del. & SAN FRANCISCO --(BUSINESS WIRE)--May 19, 2026-- Incyte (Nasdaq:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work. This press release features multimedia.

incyte.com

Tue, May 12, 2026

1 updates

INCY

9:30 AM

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi ® /Minjuvi ®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts Session Oral and poster presentations to feature new data for INCA033989, an anti-mutant calreticulin

Presentation / Abstract • Phase 3EHA Plenary Abstract Session Sat, Jun 13, 2026, 6:00 AM ETincyte.com

Thu, May 7, 2026

1 updates

INCY

8:50 AM

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) at the 2026 EADV Symposium The vast majority of

Trial Results • Phase 3incyte.com

Wed, May 6, 2026

1 updates

INCY

4:30 PM

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del. --(BUSINESS WIRE)--May 6, 2026-- Incyte Corporation (Nasdaq:INCY) announced today that it granted equity inducement awards to Suketu (Suky) Upadhyay, the Company’s new Executive Vice President and Chief Financial Officer, pursuant to the Company’s 2024 Inducement Stock Incentive

incyte.com

Fri, May 1, 2026

1 updates

INCY

5:28 PM

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi ® (ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi Jakafi XR will be available for pharmacy orders by May 8 WILMINGTON, Del.

incyte.com

Wed, Apr 29, 2026

1 updates

INCY

8:00 AM

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 29, 2026-- Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: BofA Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 1:40 pm (PDT) and RBC 2026 Global Healthcare

incyte.com

Tue, Apr 28, 2026

2 updates

INCY

7:00 AM

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi ® (ruxolitinib) net sales of $758 million, an increase of 7% compared to the same period in 2025 Opzelura ®

incyte.com

INCY

7:00 AM

Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 28, 2026-- Incyte (Nasdaq:INCY) announces the appointment of Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer (CFO) effective May 4, 2026. In his new role, Mr. Upadhyay will serve as a key member of the Executive Leadership Team

incyte.com

Tue, Apr 21, 2026

1 updates

INCY

10:00 AM

Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

- Data from pivotal frontMIND study of tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) featured in oral presentation at ASCO; results support global regulatory submissions WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 21, 2026-- Incyte (Nasdaq:INCY) today announced

Presentation / Abstract • Phase 3incyte.com